Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 6 (2009), Issue 8 (August)

1. The effect of needle bevel position on pain for subcutaneous lidocaine injection.
   J Perianesth Nurs, 24(4): 241-3. [Abstract] [Full-text]
2. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.
   Ann Surg, 250(2): 268-72. [Abstract] [Full-text]
3. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.
   Lancet, 374(9687): 379-86. [Abstract] [Full-text]
4. Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors.
   BMC Neurol, 9: 33. [Abstract] [Full-text]
5. An ex vivo toe model used to assess applicators for the iontophoretic ungual delivery of terbinafine.
   Pharm Res, 26(9): 2194-201. [Abstract] [Full-text]
6. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
   J Gastrointest Surg, 13(9): 1699-706. [Abstract] [Full-text]
7. Disagreements with implications: diverging discourses on the ethics of non-medical use of methylphenidate for performance enhancement.
   BMC Med Ethics, 10: 9. [Abstract] [Full-text]
8. Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer.
   Gynecol Oncol, 114(3): 415-9. [Abstract] [Full-text]
9. Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.
   Gynecol Oncol, 114(3): 516-22. [Abstract] [Full-text]
10. Inner blood-retinal barrier transporters: role of retinal drug delivery.
    Pharm Res, 26(9): 2055-65. [Abstract] [Full-text]
11. Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience.
    Gynecol Oncol, 114(3): 420-3. [Abstract] [Full-text]
12. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.
    Gynecol Oncol, 114(3): 424-6. [Abstract] [Full-text]
13. Determination of dual delivery for stem cell differentiation using dexamethasone and TGF-beta3 in/on polymeric microspheres.
    Biomaterials, 30(27): 4796-805. [Abstract] [Full-text]
14. Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant.
    Am J Hematol, 84(8): 484-7. [Abstract] [Full-text]
15. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors.
    Gynecol Oncol, 114(3): 431-6. [Abstract] [Full-text]
16. Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study.
    Gynecol Oncol, 114(3): 472-9. [Abstract] [Full-text]
17. Doxorubicin-polyphosphazene conjugate hydrogels for locally controlled delivery of cancer therapeutics.
    Biomaterials, 30(27): 4752-62. [Abstract] [Full-text]
18. A magnetic, luminescent and mesoporous core-shell structured composite material as drug carrier.
    Biomaterials, 30(27): 4786-95. [Abstract] [Full-text]
19. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
    Gynecol Oncol, 114(3): 410-4. [Abstract] [Full-text]
20. A chitosan hydrogel delivery system for osteosarcoma gene therapy with pigment epithelium-derived factor combined with chemotherapy.
    Biomaterials, 30(27): 4815-23. [Abstract] [Full-text]
21. Hyaluronic acid hydrogel loaded with genetically-engineered brain-derived neurotrophic factor as a neural cell carrier.
    Biomaterials, 30(27): 4581-9. [Abstract] [Full-text]
22. A surface-eroding antibiotic delivery system based on poly-(trimethylene carbonate).
    Biomaterials, 30(27): 4738-42. [Abstract] [Full-text]
23. Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial.
    Eur Heart J, 30(15): 1880-4. [Abstract] [Full-text]
24. Postexercise rehydration in man: the effects of osmolality and carbohydrate content of ingested drinks.
    Nutrition, 25(9): 905-13. [Abstract] [Full-text]
25. Neuroprotective effects of estrogen therapy for cognitive and neurobiological profiles of monkey models of menopause.
    Am J Primatol, 71(9): 794-801. [Abstract] [Full-text]
26. Sepsis due to fluoroquinolone-resistant Escherichia coli after transrectal ultrasound-guided prostate needle biopsy.
    Urology, 74(2): 332-8. [Abstract] [Full-text]
27. US guided injections in arthritis.
    Eur J Radiol, 71(2): 197-203. [Abstract] [Full-text]
28. Urinary tract infections: to prophylaxis or not to prophylaxis?
    Pediatr Nephrol, 24(9): 1605-9. [Abstract] [Full-text]
29. Age and racial/ethnic differences in the prevalence of reported symptoms in human immunodeficiency virus-infected persons on antiretroviral therapy.
    J Pain Symptom Manage, 38(2): 197-207. [Abstract] [Full-text]
30. Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patients.
    Crit Rev Oncol Hematol, 71(3): 214-21. [Abstract] [Full-text]
31. Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment.
    Crit Rev Oncol Hematol, 71(3): 249-57. [Abstract] [Full-text]
32. Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets.
    Crit Rev Oncol Hematol, 71(3): 181-98. [Abstract] [Full-text]
33. Effects of nonoral estradiol-micronized progesterone or low-dose oral estradiol-drospirenone therapy on metabolic variables and markers of endothelial function in early postmenopause.
    Fertil Steril, 92(2): 605-12. [Abstract] [Full-text]
34. Percutaneous mechanical thrombectomy combined with catheter-directed thrombolysis in the treatment of symptomatic lower extremity deep venous thrombosis.
    Eur J Radiol, 71(2): 350-5. [Abstract] [Full-text]
35. Organophosphate antidote auto-injectors vs. traditional administration: a time motion study.
    J Emerg Med, 37(2): 139-43. [Abstract] [Full-text]
36. Hospital resources for urokinase/recombinant tissue-type plasminogen activator therapy for acute stroke in Beijing.
    Surg Neurol, 72: S2-7. [Abstract] [Full-text]
37. National patterns in antidepressant medication treatment.
    Arch Gen Psychiatry, 66(8): 848-56. [Abstract] [Full-text]
38. Better prophylaxis against surgical site infection with local as well as systemic antibiotics. An in vivo study.
    J Bone Joint Surg Am, 91(8): 1907-12. [Abstract] [Full-text]
39. Clinical report--Forgoing medically provided nutrition and hydration in children.
    Pediatrics, 124(2): 813-22. [Abstract] [Full-text]
40. Needle length for immunization of early adolescents as determined by ultrasound.
    Pediatrics, 124(2): 667-72. [Abstract] [Full-text]
41. Comparison of 3 needle sizes for trigger point injection in myofascial pain syndrome of upper- and middle-trapezius muscle: a randomized controlled trial.
    Arch Phys Med Rehabil, 90(8): 1332-9. [Abstract] [Full-text]
42. Reducing immunization discomfort in 4- to 6-year-old children: a randomized clinical trial.
    Pediatrics, 124(2): e203-9. [Abstract] [Full-text]
43. Simultaneous release of multiple molecules from poly(lactide-co-glycolide) nanoparticles assembled onto medical devices.
    Biomaterials, 30(28): 4889-97. [Abstract] [Full-text]
44. Controlled drug release from multilayered phospholipid polymer hydrogel on titanium alloy surface.
    Biomaterials, 30(28): 5201-8. [Abstract] [Full-text]
45. The application of poly (glycerol-sebacate) as biodegradable drug carrier.
    Biomaterials, 30(28): 5209-14. [Abstract] [Full-text]
46. In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells.
    Biomaterials, 30(28): 5187-200. [Abstract] [Full-text]
47. In vitro cellular responses to scaffolds containing two microencapulated growth factors.
    Biomaterials, 30(28): 5215-24. [Abstract] [Full-text]
48. Chemical conjugation of urokinase to magnetic nanoparticles for targeted thrombolysis.
    Biomaterials, 30(28): 5125-30. [Abstract] [Full-text]
49. Calcium alginate beads embedded in silk fibroin as 3D dual drug releasing scaffolds.
    Biomaterials, 30(28): 5170-7. [Abstract] [Full-text]
50. An acid-labile temperature-responsive sol-gel reversible polymer for enhanced gene delivery to the myocardium and skeletal muscle cells.
    Biomaterials, 30(28): 5225-33. [Abstract] [Full-text]
51. A paradigm for peptide vaccine delivery using viral epitopes encapsulated in degradable polymer hydrogel capsules.
    Biomaterials, 30(28): 5178-86. [Abstract] [Full-text]
52. A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections.
    Ophthalmology, 116(8): 1498-501. [Abstract] [Full-text]
53. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy.
    Neurology, 73(5): 342-8. [Abstract] [Full-text]
54. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.
    J Natl Cancer Inst, 101(15): 1049-57. [Abstract] [Full-text]
55. Selective antagonism of anticancer drugs for side-effect removal.
    Trends Pharmacol Sci, 30(8): 403-10. [Abstract] [Full-text]
56. Protein-based nanomedicine platforms for drug delivery.
    Small, 5(15): 1706-21. [Abstract] [Full-text]
57. Protein transport in human cells mediated by covalently and noncovalently conjugated arginine-rich intracellular delivery peptides.
    Peptides, 30(9): 1669-78. [Abstract] [Full-text]
58. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
    Peptides, 30(9): 1643-50. [Abstract] [Full-text]
59. Photodynamic therapy with 5-aminolevulinic acid and diamino acid derivatives of protoporphyrin IX reduces papillomas in mice without eliminating transformation into squamous cell carcinoma of the skin.
    Int J Cancer, 125(7): 1721-7. [Abstract] [Full-text]
60. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review.
    Ann Oncol, 20(8): 1387-96. [Abstract] [Full-text]
61. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma.
    Ann Oncol, 20(8): 1402-7. [Abstract] [Full-text]
62. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.
    Ann Oncol, 20(8): 1344-51. [Abstract] [Full-text]
63. FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study.
    Ann Oncol, 20(8): 1383-6. [Abstract] [Full-text]
64. +331G/A variant in the progesterone receptor gene, postmenopausal hormone use and risk of breast cancer.
    Int J Cancer, 125(7): 1685-91. [Abstract] [Full-text]
65. Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study.
    Ann Oncol, 20(8): 1362-8. [Abstract] [Full-text]
66. Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study.
    Ann Oncol, 20(8): 1369-74. [Abstract] [Full-text]
67. Bio/abiotic interface constructed from nanoscale DNA dendrimer and conducting polymer for ultrasensitive biomolecular diagnosis.
    Small, 5(15): 1784-90. [Abstract] [Full-text]
68. The effects of hormone therapy decision support for women with mobility impairments.
    Health Care Women Int, 30(9): 845-54. [Abstract] [Full-text]
69. Virological response to initial antiretroviral regimens containing abacavir or tenofovir.
    J Infect Dis, 200(5): 710-4. [Abstract] [Full-text]
70. Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice.
    BMC Cancer, 9: 250. [Abstract] [Full-text]
71. Topical polyphenolic antioxidants reduce the adverse effects of intense pulsed light therapy.
    J Cosmet Laser Ther, 11(3): 142-5. [Abstract] [Full-text]
72. Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy.
    J Clin Endocrinol Metab, 94(8): 2850-6. [Abstract] [Full-text]
73. Brain glucose metabolism in hypothyroidism: a positron emission tomography study before and after thyroid hormone replacement therapy.
    J Clin Endocrinol Metab, 94(8): 2922-9. [Abstract] [Full-text]
74. Influence of direct admission to Comprehensive Stroke Centers on the outcome of acute stroke patients treated with intravenous thrombolysis.
    J Neurol, 256(8): 1270-6. [Abstract] [Full-text]
75. The role of intra-cerebrospinal fluid treatment and prophylaxis in patients with solid tumors.
    Semin Oncol, 36(4): S55-68. [Abstract] [Full-text]
76. Treatment modalities for leptomeningeal metastases.
    Semin Oncol, 36(4): S46-54. [Abstract] [Full-text]
77. Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more.
    Semin Oncol, 36(4): S25-34. [Abstract] [Full-text]
78. Central nervous system disease in hematologic malignancies: historical perspective and practical applications.
    Semin Oncol, 36(4): S2-S16. [Abstract] [Full-text]
79. Understanding the origins of gliomas and developing novel therapies: cerebrospinal fluid and subventricular zone interplay.
    Semin Oncol, 36(4): S17-24. [Abstract] [Full-text]
80. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.
    J Orthop Sci, 14(4): 397-404. [Abstract] [Full-text]
81. Prevention of tuberculosis in patients taking tumor necrosis factor-alpha blockers.
    J Rheumatol Suppl, 83: 76-7. [Abstract] [Full-text]
82. Traditional systemic treatment of psoriasis.
    J Rheumatol Suppl, 83: 46-8. [Abstract] [Full-text]
83. Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer.
    Clin Breast Cancer, 9(3): 178-83. [Abstract] [Full-text]
84. Nitric oxide-loaded echogenic liposomes for nitric oxide delivery and inhibition of intimal hyperplasia.
    J Am Coll Cardiol, 54(7): 652-9. [Abstract] [Full-text]
85. Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction.
    Am J Cardiol, 104(4): 514-8. [Abstract] [Full-text]
86. Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction.
    Am J Cardiol, 104(4): 475-9. [Abstract] [Full-text]
87. The Hedgehog signalling pathway as a therapeutic target in early breast cancer development.
    Expert Opin Ther Targets, 13(9): 1095-103. [Abstract] [Full-text]
88. Therapeutic potential of endothelin receptor modulators: lessons from human clinical trials.
    Expert Opin Ther Targets, 13(9): 1069-84. [Abstract] [Full-text]
89. Therapeutic targets for new therapy for corticosteroid refractory asthma.
    Expert Opin Ther Targets, 13(9): 1053-67. [Abstract] [Full-text]
90. Targeting FtsZ for antibacterial therapy: a promising avenue.
    Expert Opin Ther Targets, 13(9): 1037-51. [Abstract] [Full-text]
91. RNA interference screening for the discovery of oncology targets.
    Expert Opin Ther Targets, 13(9): 1027-35. [Abstract] [Full-text]
92. Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis.
    Expert Opin Ther Targets, 13(9): 1121-34. [Abstract] [Full-text]
93. Phospho-p70S6K and cdc2/cdk1 as therapeutic targets for diffuse large B-cell lymphoma.
    Expert Opin Ther Targets, 13(9): 1085-93. [Abstract] [Full-text]
94. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
    J Clin Oncol, 27(23): 3778-85. [Abstract] [Full-text]
95. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
    J Clin Oncol, 27(23): 3764-71. [Abstract] [Full-text]
96. Capture of drug targets from live cells using a multipurpose immuno-chemo-proteomics tool.
    J Proteome Res, 8(8): 3951-7. [Abstract] [Full-text]
97. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
    J Clin Oncol, 27(23): 3830-5. [Abstract] [Full-text]
98. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.
    J Clin Oncol, 27(23): 3786-93. [Abstract] [Full-text]
99. Management of deep-seated malformations with photodynamic therapy: a new guiding imaging modality.
    Lasers Med Sci, 24(5): 769-75. [Abstract] [Full-text]
100. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
     Am J Clin Oncol, 32(4): 348-52. [Abstract] [Full-text]
101. Intracellular free calcium mediates glioma cell detachment and cytotoxicity after photodynamic therapy.
     Lasers Med Sci, 24(5): 777-86. [Abstract] [Full-text]
102. Assessing cost effectiveness of empirical and prophylactic therapy for managing leptospirosis outbreaks.
     Epidemiol Infect, 137(9): 1323-32. [Abstract] [Full-text]
103. Markov modelling of HIV infection evolution in the HAART era.
     Epidemiol Infect, 137(9): 1272-82. [Abstract] [Full-text]
104. Optimal conditions for successful ablation of high-grade dysplasia in Barrett's oesophagus using aminolaevulinic acid photodynamic therapy.
     Lasers Med Sci, 24(5): 729-34. [Abstract] [Full-text]
105. Photodynamic therapy as adjunct to non-surgical periodontal treatment in patients on periodontal maintenance: a randomized controlled clinical trial.
     Lasers Med Sci, 24(5): 681-8. [Abstract] [Full-text]
106. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants.
     Pediatr Infect Dis J, 28(8): 702-6. [Abstract] [Full-text]
107. Guidelines for prehospital fluid resuscitation in the injured patient.
     J Trauma, 67(2): 389-402. [Abstract] [Full-text]
108. Resuscitation of severely burned military casualties: fluid begets more fluid.
     J Trauma, 67(2): 231-7; discussion 237. [Abstract] [Full-text]
109. Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma.
     Arch Ophthalmol, 127(8): 1043-7. [Abstract] [Full-text]
110. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy.
     Am J Health Syst Pharm, 66(16): 1471-7. [Abstract] [Full-text]
111. Stimulus-responsive targeted nanomicelles for effective cancer therapy.
     Nanomed, 4(6): 657-67. [Abstract] [Full-text]
112. Potential novel drug carriers for inner ear treatment: hyperbranched polylysine and lipid nanocapsules.
     Nanomed, 4(6): 623-35. [Abstract] [Full-text]
113. Uses of nanoparticles for central nervous system imaging and therapy.
     AJNR Am J Neuroradiol, 30(7): 1293-301. [Abstract] [Full-text]
114. Errors in administration of parenteral medications are a serious safety problem in intensive care units.
     Aust Crit Care, 22(3): 141-3. [Abstract] [Full-text]
115. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.
     Mol Cancer, 8: 47. [Abstract] [Full-text]
116. Endophthalmitis after intravitreal injections.
     Expert Opin Pharmacother, 10(13): 2119-26. [Abstract] [Full-text]
117. Preparation of core-shell biodegradable microfibers for long-term drug delivery.
     J Biomed Mater Res A, 90(4): 1243-51. [Abstract] [Full-text]
118. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
     Qual Life Res, 18(7): 853-61. [Abstract] [Full-text]
119. Pegylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis.
     J Neuroimmunol, 213(1): 20-5. [Abstract] [Full-text]
120. Postmenopausal hormone therapy and the risk of cardiovascular disease.
     Expert Opin Pharmacother, 10(13): 2041-53. [Abstract] [Full-text]
121. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy.
     J Virol, 83(17): 8470-81. [Abstract] [Full-text]
122. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen.
     J Biol Chem, 284(33): 22379-89. [Abstract] [Full-text]
123. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma.
     Cancer, 115(16): 3640-50. [Abstract] [Full-text]
124. Safety of long-acting beta-agonists: are new data really required?
     Chest, 136(2): 604-7. [Abstract] [Full-text]
125. Nanocarriers' entry into the cell: relevance to drug delivery.
     Cell Mol Life Sci, 66(17): 2873-96. [Abstract] [Full-text]
126. Avidin fusion protein-expressing lentiviral vector for targeted drug delivery.
     Hum Gene Ther, 20(8): 871-82. [Abstract] [Full-text]
127. Is full postpleurodesis lung expansion a determinant of a successful outcome after talc pleurodesis?
     Chest, 136(2): 361-8. [Abstract] [Full-text]
128. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma.
     BJU Int, 104(4): 456-60. [Abstract] [Full-text]
129. Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection.
     J Neurooncol, 94(2): 203-12. [Abstract] [Full-text]
130. Enhanced flexor tendon healing through controlled delivery of PDGF-BB.
     J Orthop Res, 27(9): 1209-15. [Abstract] [Full-text]
131. Anticholinergic premedication for flexible bronchoscopy: a randomized, double-blind, placebo-controlled study of atropine and glycopyrrolate.
     Chest, 136(2): 347-54. [Abstract] [Full-text]
132. Results of long-term follow-up of photodynamic therapy for roentgenographically occult bronchogenic squamous cell carcinoma.
     Chest, 136(2): 369-75. [Abstract] [Full-text]
133. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma.
     Eur J Surg Oncol, 35(9): 980-5. [Abstract] [Full-text]
134. A novel synthetic route for the preparation of hydrolytically degradable synthetic hydrogels.
     J Biomed Mater Res A, 90(4): 1073-82. [Abstract] [Full-text]
135. A novel model and experimental analysis of hydrophilic and hydrophobic agent release from biodegradable polymers.
     J Biomed Mater Res A, 90(4): 1054-65. [Abstract] [Full-text]
136. Preparation, characterization, in-vitro drug release and cellular uptake of poly(caprolactone) grafted dextran copolymeric nanoparticles loaded with anticancer drug.
     J Biomed Mater Res A, 90(4): 1128-36. [Abstract] [Full-text]
137. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.
     Br J Cancer, 101(4): 615-20. [Abstract] [Full-text]
138. Real medical benefit assessed by indirect comparison.
     Therapie, 64(3): 225-32. [Abstract] [Full-text]
139. Value of post-registration studies for reimbursement renewal.
     Therapie, 64(3): 203-13. [Abstract] [Full-text]
140. Evaluation and validation of diagnostic tests for guiding therapeutic decisions.
     Therapie, 64(3): 187-201. [Abstract] [Full-text]
141. Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study.
     Br J Cancer, 101(4): 598-604. [Abstract] [Full-text]
142. Peripheral neural cell sensitivity to mTHPC-mediated photodynamic therapy in a 3D in vitro model.
     Br J Cancer, 101(4): 658-65. [Abstract] [Full-text]
143. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit.
     J Antimicrob Chemother, 64(3): 625-9. [Abstract] [Full-text]
144. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation.
     J Antimicrob Chemother, 64(3): 579-88. [Abstract] [Full-text]
145. Early outcome of combined thrombolysis based on the mismatch on perfusion CT.
     Cerebrovasc Dis, 28(3): 259-65. [Abstract] [Full-text]
146. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data.
     J Antimicrob Chemother, 64(3): 599-606. [Abstract] [Full-text]
147. Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment.
     Nicotine Tob Res, 11(9): 1067-75. [Abstract] [Full-text]
148. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia.
     Leukemia, 23(8): 1374-7. [Abstract] [Full-text]
149. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial.
     Leukemia, 23(8): 1410-6. [Abstract] [Full-text]
150. Micrometastases or isolated tumor cells and the outcome of breast cancer.
     N Engl J Med, 361(7): 653-63. [Abstract] [Full-text]
151. Surgical resection of renal cell carcinoma after targeted therapy.
     J Urol, 182(3): 881-6. [Abstract] [Full-text]
152. Photodynamic therapy for cholangiocarcinoma: overview and new developments.
     Curr Opin Gastroenterol, 25(5): 472-6. [Abstract] [Full-text]
153. Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
     Head Neck, 31(9): 1121-8. [Abstract] [Full-text]
154. Accelerated fractionation head and neck intensity-modulated radiation therapy and concurrent chemotherapy in the community setting: safety and efficacy considerations.
     Head Neck, 31(9): 1144-51. [Abstract] [Full-text]
155. Economic burden of unjustified medications at hospital discharge.
     Swiss Med Wkly, 139(29): 430-5. [Abstract] [Full-text]
156. Correlations between computerized battery testing and a memory questionnaire for identification of neurocognitive impairment in HIV type 1-infected subjects on stable antiretroviral therapy.
     AIDS Res Hum Retroviruses, 25(8): 765-9. [Abstract] [Full-text]
157. A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo.
     Cancer Res, 69(16): 6531-8. [Abstract] [Full-text]
158. Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma.
     Cancer Res, 69(16): 6573-80. [Abstract] [Full-text]
159. Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study.
     Lancet Neurol, 8(9): 802-9. [Abstract] [Full-text]
160. Targeted delivery of anti-coxsackievirus siRNAs using ligand-conjugated packaging RNAs.
     Antiviral Res, 83(3): 307-16. [Abstract] [Full-text]
161. Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases.
     Ann Surg Oncol, 16(9): 2470-8. [Abstract] [Full-text]
162. Outcome of locally recurrent and metastatic angiosarcoma.
     Ann Surg Oncol, 16(9): 2502-9. [Abstract] [Full-text]
163. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis.
     Ann Surg Oncol, 16(9): 2570-8. [Abstract] [Full-text]
164. Use of intermittent preventive treatment for malaria by pregnant women in Buea, Cameroon.
     Acta Trop, 112(1): 54-8. [Abstract] [Full-text]
165. A fully implanted drug delivery system for peripheral nerve blocks in behaving animals.
     J Neurosci Methods, 182(2): 165-71. [Abstract] [Full-text]
166. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
     Blood, 114(7): 1299-305. [Abstract] [Full-text]
167. Postoperative prophylactic antibiotics and surgical site infection rates in breast surgery patients.
     Ann Surg Oncol, 16(9): 2464-9. [Abstract] [Full-text]
168. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors.
     Blood, 114(7): 1306-13. [Abstract] [Full-text]
169. Impact of preoperative nesiritide on renal function after mitral valve surgery.
     Heart Surg Forum, 12(4): E217-8. [Abstract] [Full-text]
170. Physical activity and diet behaviour in colorectal cancer patients receiving chemotherapy: associations with quality of life.
     BMC Gastroenterol, 9: 60. [Abstract] [Full-text]
171. Diffusion tensor imaging in cocaine dependence: regional effects of cocaine on corpus callosum and effect of cocaine administration route.
     Drug Alcohol Depend, 104(3): 262-7. [Abstract] [Full-text]
172. Documenting and improving opioid treatment: the Prescription Opioid Documentation and Surveillance (PODS) System.
     Pain Med, 10(5): 866-77. [Abstract] [Full-text]
173. Comparison of two mechanical intraosseous infusion devices: a pilot, randomized crossover trial.
     Resuscitation, 80(9): 1029-33. [Abstract] [Full-text]
174. Assessing the effect of a polypharmacy medication adherence simulation project in a geriatrics course in a college of pharmacy.
     J Am Geriatr Soc, 57(8): 1487-91. [Abstract] [Full-text]
175. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.
     J Am Geriatr Soc, 57(8): 1403-10. [Abstract] [Full-text]
176. Computerized decision support to reduce potentially inappropriate prescribing to older emergency department patients: a randomized, controlled trial.
     J Am Geriatr Soc, 57(8): 1388-94. [Abstract] [Full-text]
177. Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles.
     J Control Release, 138(3): 268-76. [Abstract] [Full-text]
178. Evaluation of a degradable shape-memory polymer network as matrix for controlled drug release.
     J Control Release, 138(3): 243-50. [Abstract] [Full-text]
179. Fabrication of biodegradable spheroidal microparticles for drug delivery applications.
     J Control Release, 138(3): 235-42. [Abstract] [Full-text]
180. The extended release properties of HPMC matrices in the presence of dietary sugars.
     J Control Release, 138(3): 251-9. [Abstract] [Full-text]
181. Thrombin-sensitive photodynamic agents: a novel strategy for selective synovectomy in rheumatoid arthritis.
     J Control Release, 138(3): 225-34. [Abstract] [Full-text]
182. An injectable drug delivery platform for sustained combination therapy.
     J Control Release, 138(3): 205-13. [Abstract] [Full-text]
183. Effects of antidepressant treatment on antiretroviral regimen adherence among depressed HIV-infected patients.
     Psychiatr Q, 80(3): 131-41. [Abstract] [Full-text]
184. Magnetic resonance imaging tracking of alginate beads used for drug delivery of growth factors at sites of cardiac damage.
     Magn Reson Imaging, 27(7): 970-5. [Abstract] [Full-text]
185. Application of novel dual wave meal bolus and its impact on glycated hemoglobin A1c level in children with type 1 diabetes.
     Pediatr Diabetes, 10(5): 298-303. [Abstract] [Full-text]
186. Multiple daily injections in young patients using the ezy-BICC bolus insulin calculation card, compared to mixed insulin and CSII.
     Pediatr Diabetes, 10(5): 304-9. [Abstract] [Full-text]
187. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing.
     J Psychopharmacol, 23(7): 789-96. [Abstract] [Full-text]
188. Endovascular treatment of experimental aneurysms using a combination of thermoreversible gelation polymer and protection devices: feasibility study.
     Neurosurgery, 65(3): 601-9; discussion 609. [Abstract] [Full-text]
189. Anatomic compression caused by high-volume convection-enhanced delivery to the brain.
     Neurosurgery, 65(3): 579-85; discussion 585-6. [Abstract] [Full-text]
190. Manual physical therapy and exercise versus electrophysical agents and exercise in the management of plantar heel pain: a multicenter randomized clinical trial.
     J Orthop Sports Phys Ther, 39(8): 573-85. [Abstract] [Full-text]
191. Photodynamic therapy for head and neck dysplasia and cancer.
     Arch Otolaryngol Head Neck Surg, 135(8): 784-8. [Abstract] [Full-text]
192. Postchemotherapy histiocyte-rich pseudotumor involving the spleen.
     Am J Clin Pathol, 132(3): 342-8. [Abstract] [Full-text]
193. Exertional dysnatremia in collapsed marathon runners: a critical role for point-of-care testing to guide appropriate therapy.
     Am J Clin Pathol, 132(3): 336-40. [Abstract] [Full-text]
194. Layered double hydroxide nanoparticles in gene and drug delivery.
     Expert Opin Drug Deliv, 6(9): 907-22. [Abstract] [Full-text]
195. Fighting tuberculosis: old drugs, new formulations.
     Expert Opin Drug Deliv, 6(9): 977-93. [Abstract] [Full-text]
196. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy.
     J Infect Dis, 200(6): 935-46. [Abstract] [Full-text]
197. Characterization of iron oxide nanoparticles adsorbed with cisplatin for biomedical applications.
     Phys Med Biol, 54(17): 5109-21. [Abstract] [Full-text]
198. Nanodiamonds as vehicles for systemic and localized drug delivery.
     Expert Opin Drug Deliv, 6(9): 883-95. [Abstract] [Full-text]
199. Delivery of antibiotics to the respiratory tract: an update.
     Expert Opin Drug Deliv, 6(9): 897-905. [Abstract] [Full-text]
200. Chitosan and its salts for mucosal and transmucosal delivery.
     Expert Opin Drug Deliv, 6(9): 923-39. [Abstract] [Full-text]
201. Assessment methods of inhaled aerosols: technical aspects and applications.
     Expert Opin Drug Deliv, 6(9): 941-59. [Abstract] [Full-text]
202. The acute effects of CMF-based chemotherapy on maxillary periodontal microcirculation.
     Cancer Chemother Pharmacol, 64(5): 1047-52. [Abstract] [Full-text]
203. Novel treatment of medullary thyroid cancer.
     Curr Opin Endocrinol Diabetes Obes, 16(5): 367-72. [Abstract] [Full-text]
204. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.
     J Pharmacokinet Pharmacodyn, 36(4): 341-51. [Abstract] [Full-text]
205. Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture.
     Acc Chem Res, 42(8): 1141-51. [Abstract] [Full-text]
206. Collagen-gentamicin implant for prevention of sternal wound infection; long-term follow-up of effectiveness.
     Interact Cardiovasc Thorac Surg, 9(3): 454-8. [Abstract] [Full-text]
207. Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP.
     J Cancer Res Clin Oncol, 135(10): 1421-8. [Abstract] [Full-text]
208. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
     Cancer Chemother Pharmacol, 64(5): 1001-7. [Abstract] [Full-text]
209. Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients.
     Cancer Chemother Pharmacol, 64(5): 901-5. [Abstract] [Full-text]
210. Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.
     Cancer Chemother Pharmacol, 64(5): 917-24. [Abstract] [Full-text]
211. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.
     Cancer Chemother Pharmacol, 64(5): 907-16. [Abstract] [Full-text]
212. Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
     Cancer Chemother Pharmacol, 64(5): 953-60. [Abstract] [Full-text]
213. Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer.
     Cancer Chemother Pharmacol, 64(5): 877-83. [Abstract] [Full-text]
214. Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.
     Cancer Chemother Pharmacol, 64(5): 893-9. [Abstract] [Full-text]
215. The neuraxial effects of intraspinal amitriptyline at low concentrations.
     Anesth Analg, 109(3): 965-71. [Abstract] [Full-text]
216. Therapeutic errors involving adults in the community setting: nature, causes and outcomes.
     Aust N Z J Public Health, 33(4): 388-94. [Abstract] [Full-text]
217. Neuropeptide and sigma receptors as novel therapeutic targets for the pharmacotherapy of depression.
     CNS Drugs, 23(9): 755-72. [Abstract] [Full-text]
218. Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence.
     CNS Drugs, 23(9): 713-25. [Abstract] [Full-text]
219. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer.
     Br J Surg, 96(9): 1015-22. [Abstract] [Full-text]
220. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
     J Clin Oncol, 27(24): 3908-15. [Abstract] [Full-text]
221. Dynamic changes in arterial waveform derived variables and fluid responsiveness in mechanically ventilated patients: a systematic review of the literature.
     Crit Care Med, 37(9): 2642-7. [Abstract] [Full-text]
222. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients.
     Cancer Immunol Immunother, 58(11): 1843-52. [Abstract] [Full-text]
223. Multicenter randomized trial of facilitated percutaneous coronary intervention with low-dose tenecteplase in patients with acute myocardial infarction: the Athens PCI trial.
     Catheter Cardiovasc Interv, 74(3): 398-405. [Abstract] [Full-text]
224. Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium.
     Cancer Chemother Pharmacol, 64(6): 1079-83. [Abstract] [Full-text]
225. The place of premedication in pediatric practice.
     Paediatr Anaesth, 19(9): 817-28. [Abstract] [Full-text]
226. Stearoyl-CoA desaturase inhibitors: update on patented compounds.
     Expert Opin Ther Pat, 19(9): 1169-91. [Abstract] [Full-text]
227. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy.
     J Virol, 83(18): 9247-57. [Abstract] [Full-text]
228. Transport molecules using reverse sequence HIV-Tat polypeptides: not just any old Tat? (WO200808225).
     Expert Opin Ther Pat, 19(9): 1329-33. [Abstract] [Full-text]
229. Morphologic changes in ovarian carcinoma after neoadjuvant chemotherapy: report of a case showing extensive clear cell changes mimicking clear cell carcinoma.
     Int J Gynecol Pathol, 28(5): 442-6. [Abstract] [Full-text]
230. Supporting staff recovery and reintegration after a critical incident resulting in infant death.
     Adv Neonatal Care, 9(4): 163-71; quiz 172-3. [Abstract] [Full-text]
231. Uptake of apolipoprotein E fragment coupled liposomes by cultured brain microvessel endothelial cells and intact brain capillaries.
     J Drug Target, 17(8): 610-8. [Abstract] [Full-text]
232. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles.
     J Drug Target, 17(8): 564-74. [Abstract] [Full-text]
233. A review of the role of emergency nurses in management of chemotherapy-related complications.
     J Clin Nurs, 18(18): 2649-55. [Abstract] [Full-text]
234. Nurse prescribing by children's nurses: views of doctors and clinical leads in one specialist children's hospital.
     J Clin Nurs, 18(18): 2668-75. [Abstract] [Full-text]
235. Response surface methodology: an extensive potential to optimize in vivo photodynamic therapy conditions.
     Int J Radiat Oncol Biol Phys, 75(1): 244-52. [Abstract] [Full-text]
236. Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression.
     J Drug Target, 17(8): 627-37. [Abstract] [Full-text]
237. Toward the understanding of the photodynamic activity of m-THPP encapsulated in PLGA nanoparticles: correlation between nanoparticle properties and in vivo activity.
     J Drug Target, 17(8): 599-609. [Abstract] [Full-text]
238. Quenching-induced deactivation of photosensitizer by nanoencapsulation to improve phototherapy of cancer.
     J Drug Target, 17(8): 619-26. [Abstract] [Full-text]
239. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery.
     Int J Pharm, 379(1): 131-8. [Abstract] [Full-text]
240. Nanoparticles for direct nose-to-brain delivery of drugs.
     Int J Pharm, 379(1): 146-57. [Abstract] [Full-text]
241. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma.
     Cancer Sci, 100(9): 1591-6. [Abstract] [Full-text]
242. Effect on the nasal bioavailability of co-processing drug and bioadhesive carrier via spray-drying.
     Int J Pharm, 379(1): 67-71. [Abstract] [Full-text]
243. Dose tolerability of chronically inhaled voriconazole solution in rodents.
     Int J Pharm, 379(1): 25-31. [Abstract] [Full-text]
244. Target-selective degradation of cancer-related proteins by novel photosensitizers for molecular-targeted photodynamic therapy.
     Cancer Sci, 100(9): 1581-4. [Abstract] [Full-text]
245. The physiology of colonic hydrotherapy.
     Colorectal Dis, 11(7): 686-8. [Abstract] [Full-text]
246. Fast-responsive porous thermoresponsive microspheres for controlled delivery of macromolecules.
     Int J Pharm, 379(1): 9-17. [Abstract] [Full-text]
247. Macromolecular drug delivery: basic principles and therapeutic applications.
     Mol Biotechnol, 43(1): 89-94. [Abstract] [Full-text]
248. Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland.
     Eur J Clin Pharmacol, 65(9): 927-33. [Abstract] [Full-text]
249. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.
     Int J Radiat Oncol Biol Phys, 75(1): 143-9. [Abstract] [Full-text]
250. Phase I study of oral S-1 plus Cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
     Int J Radiat Oncol Biol Phys, 75(1): 109-14. [Abstract] [Full-text]
251. Do patients require outpatient follow-up after rapid referral double contrast barium enema?
     Colorectal Dis, 11(7): 729-32. [Abstract] [Full-text]
252. A mapping of drug space from the viewpoint of small molecule metabolism.
     PLoS Comput Biol, 5(8): e1000474. [Abstract] [Full-text]
253. Influence of different polymer types on the overall release mechanism in hydrophilic matrix tablets.
     Molecules, 14(8): 2699-716. [Abstract] [Full-text]
254. Physical carboxymethylscleroglucan/calcium ion hydrogels as modified drug delivery systems in topical formulations.
     Molecules, 14(8): 2684-98. [Abstract] [Full-text]
255. Antimicrobial prophylaxis for cesarean delivery before skin incision.
     Obstet Gynecol, 114(3): 573-9. [Abstract] [Full-text]
256. The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.
     Ann Thorac Surg, 88(3): 945-50; discussion 950-1. [Abstract] [Full-text]
257. Changes in pulmonary function tests after neoadjuvant therapy predict postoperative complications.
     Ann Thorac Surg, 88(3): 930-5; discussion 935-6. [Abstract] [Full-text]
258. Trimodality therapy for malignant pleural mesothelioma.
     Ann Thorac Surg, 88(3): 870-5; discussion 876. [Abstract] [Full-text]
259. Prophylaxis to prevent infective endocarditis: to use or not to use?
     Clin Cardiol, 32(8): 429-33. [Abstract] [Full-text]
260. Nanolitre liquid patterning in aqueous environments for spatially defined reagent delivery to mammalian cells.
     Nat Mater, 8(9): 736-41. [Abstract] [Full-text]
261. Isolated limb perfusion with tissue plasminogen activator for acute hand ischemia.
     J Vasc Surg, 50(3): 659-62. [Abstract] [Full-text]
262. Organic electronics for precise delivery of neurotransmitters to modulate mammalian sensory function.
     Nat Mater, 8(9): 742-6. [Abstract] [Full-text]
263. Coma resulting from spontaneous intracranial hypotension treated with the epidural blood patch in the Trendelenburg position pre-medicated with acetazolamide.
     Clin Neurol Neurosurg, 111(8): 699-702. [Abstract] [Full-text]
264. Differential diagnosis and treatment of primary, cutaneous, anaplastic large cell lymphoma: not always an easy task.
     Int J Hematol, 90(2): 226-9. [Abstract] [Full-text]
265. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men.
     Eur J Endocrinol, 161(3): 443-9. [Abstract] [Full-text]
266. Predictors of response to percutaneous ethanol sclerotherapy (PES) in patients with venous malformations: analysis of patient self-assessment and imaging.
     J Vasc Surg, 50(3): 581-9, 589.e1. [Abstract] [Full-text]
267. Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy.
     Acta Radiol, 50(7): 716-21. [Abstract] [Full-text]
268. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.
     Eur J Cancer, 45(13): 2298-303. [Abstract] [Full-text]
269. Capecitabine and vinorelbine in metastatic breast cancer.
     Eur J Cancer, 45(13): 2253-65. [Abstract] [Full-text]
270. Treatment of disseminated paraganglioma with gemcitabine and docetaxel.
     Pediatr Blood Cancer, 53(4): 663-5. [Abstract] [Full-text]
271. Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer.
     Surg Oncol, 18(3): 219-32. [Abstract] [Full-text]
272. Premedication before intubation in UK neonatal units: a decade of change?
     Arch Dis Child Fetal Neonatal Ed, 94(5): F332-5. [Abstract] [Full-text]
273. Detection of intake of nonsteroidal anti-inflammatory drugs in elderly patients with heart failure. How to ask the patient?
     Swiss Med Wkly, 139(33): 481-5. [Abstract] [Full-text]
274. Components of recommended asthma care and the use of long-term control medication among urban children with asthma.
     Med Care, 47(9): 940-7. [Abstract] [Full-text]
275. Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer.
     J Thorac Oncol, 4(9): 1170-3. [Abstract] [Full-text]
276. A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium.
     J Thorac Oncol, 4(9): 1163-9. [Abstract] [Full-text]
277. Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.
     J Thorac Oncol, 4(9): 1156-62. [Abstract] [Full-text]
278. Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device.
     J Pharm Pharmacol, 61(9): 1219-28. [Abstract] [Full-text]
279. Freeze-dried liposomes as potential carriers for ocular administration of cytochrome c against selenite cataract formation.
     J Pharm Pharmacol, 61(9): 1171-8. [Abstract] [Full-text]
280. Mannose 6-phosphate-modified bovine serum albumin nanoparticles for controlled and targeted delivery of sodium ferulate for treatment of hepatic fibrosis.
     J Pharm Pharmacol, 61(9): 1155-61. [Abstract] [Full-text]
281. Aminolevulinic acid-loaded Witepsol microparticles manufactured using a spray congealing procedure: implications for topical photodynamic therapy.
     J Pharm Pharmacol, 61(9): 1125-35. [Abstract] [Full-text]
282. Dendrimers as therapeutic agents: a systematic review.
     J Pharm Pharmacol, 61(8): 989-1003. [Abstract] [Full-text]
283. Impact of metabolic syndrome on coronary patency after thrombolytic therapy for acute myocardial infarction.
     Coron Artery Dis, 20(6): 387-91. [Abstract] [Full-text]
284. Does preoperative core needle biopsy increase surgical site infections in breast cancer surgery? Randomized study of antibiotic prophylaxis.
     Surg Infect (Larchmt), 10(4): 317-21. [Abstract] [Full-text]
285. The relationship between variations in antipsychotic prescribing across nursing homes and short-term mortality: quality of care implications.
     Med Care, 47(9): 1000-8. [Abstract] [Full-text]
286. An evaluation of the relationship between the implementation of a newly designed prescription drug label at Target pharmacies and health outcomes.
     Med Care, 47(9): 1031-5. [Abstract] [Full-text]
287. A phase II study of weekly docetaxel-cisplatin as first-line treatment for advanced non-small cell lung cancer.
     J Thorac Oncol, 4(9): 1144-7. [Abstract] [Full-text]
288. Enhanced permeability of charged dendrimers across tense lipid bilayer membranes.
     ACS Nano, 3(8): 2171-6. [Abstract] [Full-text]
289. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial.
     J Thorac Oncol, 4(9): 1148-55. [Abstract] [Full-text]
290. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.
     Ann Oncol, 20(9): 1589-95. [Abstract] [Full-text]
291. Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer.
     Ann Oncol, 20(9): 1565-75. [Abstract] [Full-text]
292. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.
     Ann Oncol, 20(9): 1529-34. [Abstract] [Full-text]
293. Feasibility of self-expandable metallic stent plus chemotherapy for metastatic gastric cancer with pyloric stenosis.
     J Gastroenterol Hepatol, 24(8): 1358-64. [Abstract] [Full-text]
294. Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02).
     Ann Oncol, 20(9): 1522-8. [Abstract] [Full-text]
295. Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis.
     J Acquir Immune Defic Syndr, 52(1): 106-13. [Abstract] [Full-text]
296. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.
     Am J Ophthalmol, 148(3): 396-408. [Abstract] [Full-text]
297. Simultaneous drug release at different rates from biodegradable polyurethane foams.
     Acta Biomater, 5(7): 2398-408. [Abstract] [Full-text]
298. Colloidal carrier integrating biomaterials for oral insulin delivery: Influence of component formulation on physicochemical and biological parameters.
     Acta Biomater, 5(7): 2475-84. [Abstract] [Full-text]
299. Intrinsic porosity of calcium phosphate cements and its significance for drug delivery and tissue engineering applications.
     Acta Biomater, 5(7): 2752-62. [Abstract] [Full-text]
300. Alpha,beta-poly(L-aspartate-graft-PEI): A pseudo-branched PEI as a gene carrier with low toxicity and high transfection efficiency.
     Acta Biomater, 5(7): 2485-94. [Abstract] [Full-text]
301. Gene expression profile on chitosan/rhBMP-2 films: A novel osteoinductive coating for implantable materials.
     Acta Biomater, 5(7): 2633-46. [Abstract] [Full-text]
302. Dose effect of dual delivery of vascular endothelial growth factor and bone morphogenetic protein-2 on bone regeneration in a rat critical-size defect model.
     Tissue Eng Part A, 15(9): 2347-62. [Abstract] [Full-text]
303. Biofunctionalized electrospun silk mats as a topical bioactive dressing for accelerated wound healing.
     Acta Biomater, 5(7): 2570-8. [Abstract] [Full-text]
304. Peroxisome proliferator-activated receptor gamma (PPAR) agonism reduces the insulin-stimulated increase in circulating interleukin-6 in GH replaced GH-deficient adults.
     Clin Endocrinol (Oxf), 71(3): 363-8. [Abstract] [Full-text]
305. Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months.
     Clin Endocrinol (Oxf), 71(3): 351-7. [Abstract] [Full-text]
306. Cyclodextrin carriers of positively charged porphyrin sensitizers.
     Org Biomol Chem, 7(18): 3797-804. [Abstract] [Full-text]
307. Synthesis, radiosynthesis and biological evaluation of 1,4-dihydroquinoline derivatives as new carriers for specific brain delivery.
     Org Biomol Chem, 7(18): 3666-73. [Abstract] [Full-text]
308. Neoadjuvant polychemotherapy in locally advanced Merkel cell carcinoma.
     Nat Rev Clin Oncol, 6(9): 544-8. [Abstract] [Full-text]
309. Patients' assessment of the convenience of fentanyl HCl iontophoretic transdermal system (ITS) versus morphine intravenous patient-controlled analgesia (IV PCA) in the management of postoperative pain after major surgery.
     Pain Manag Nurs, 10(3): 124-33. [Abstract] [Full-text]
310. Antibiotic prophylaxis in acute necrotizing pancreatitis revisited.
     Ann Pharmacother, 43(9): 1486-95. [Abstract] [Full-text]
311. Life-threatening flecainide intoxication in a young child secondary to medication error.
     Ann Pharmacother, 43(9): 1522-7. [Abstract] [Full-text]
312. Perioperative anticoagulation for patients with mechanic heart valve(s) undertaking pacemaker implantation.
     Europace, 11(9): 1183-7. [Abstract] [Full-text]
313. Evidence-based prescription of antibiotics in urology: a 5-year review of microbiology.
     BJU Int, 104(6): 760-4. [Abstract] [Full-text]
314. In vitro method to characterize diffusion of dye from polymeric particles: a model for drug release.
     Langmuir, 25(17): 10007-13. [Abstract] [Full-text]
315. Photodynamic therapy inhibits P-glycoprotein mediated multidrug resistance via JNK activation in human hepatocellular carcinoma using the photosensitizer pheophorbide a.
     Mol Cancer, 8: 56. [Abstract] [Full-text]
316. Bilateral asymmetric popliteal entrapment syndrome treated with successful surgical decompression and adjunctive thrombolysis.
     Vasc Endovascular Surg, 43(4): 395-8. [Abstract] [Full-text]
317. Use of medications by people with chronic fatigue syndrome and healthy persons: a population-based study of fatiguing illness in Georgia.
     Health Qual Life Outcomes, 7: 67. [Abstract] [Full-text]
318. Drug-regulatable cancer cell death induced by BID under control of the tissue-specific, lung cancer-targeted TTS promoter system.
     Int J Cancer, 125(8): 1975-84. [Abstract] [Full-text]
319. Are RAS mutations predictive markers of resistance to standard chemotherapy?
     Nat Rev Clin Oncol, 6(9): 528-34. [Abstract] [Full-text]
320. Intravenous thrombolysis for acute ischemic stroke: the Malabar experience 2003 to 2008.
     J Clin Neurosci, 16(10): 1276-8. [Abstract] [Full-text]
321. Polymer-mesoporous silica materials templated with an oppositely charged surfactant/polymer system for drug delivery.
     Langmuir, 25(17): 10159-64. [Abstract] [Full-text]
322. Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women.
     Cancer, 115(17): 3848-57. [Abstract] [Full-text]
323. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.
     Cancer, 115(17): 3887-96. [Abstract] [Full-text]
324. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.
     BJU Int, 104(6): 806-12. [Abstract] [Full-text]
325. PEGylation strategies for active targeting of PLA/PLGA nanoparticles.
     J Biomed Mater Res A, 91(1): 263-76. [Abstract] [Full-text]
326. Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy.
     J Biomed Mater Res A, 91(1): 209-20. [Abstract] [Full-text]
327. Cytocompatibility studies of an in situ photopolymerized thermoresponsive hydrogel nanoparticle system using human aortic smooth muscle cells.
     J Biomed Mater Res A, 91(1): 52-9. [Abstract] [Full-text]
328. Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development.
     Fundam Clin Pharmacol, 23(4): 387-409. [Abstract] [Full-text]
329. Tetrapeptide-based hydrogels: for encapsulation and slow release of an anticancer drug at physiological pH.
     J Phys Chem B, 113(35): 11787-92. [Abstract] [Full-text]
330. Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients.
     J Surg Oncol, 100(4): 331-4. [Abstract] [Full-text]
331. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
     J Surg Oncol, 100(4): 317-20. [Abstract] [Full-text]
332. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery.
     J Surg Oncol, 100(4): 311-6. [Abstract] [Full-text]
333. Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer.
     J Surg Oncol, 100(4): 306-10. [Abstract] [Full-text]
334. Learning curve in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
     J Surg Oncol, 100(4): 293-6. [Abstract] [Full-text]
335. Indications and patient selection for cytoreductive surgery and perioperative intraperitoneal chemotherapy.
     J Surg Oncol, 100(4): 287-92. [Abstract] [Full-text]
336. Glioblastoma targeting via integrins is concentration dependent.
     Biotechnol Bioeng, 104(2): 408-17. [Abstract] [Full-text]
337. The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis.
     Stroke, 40(9): 3113-20. [Abstract] [Full-text]
338. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.
     J Nucl Med, 50(9): 1435-40. [Abstract] [Full-text]
339. Hormone therapy attenuates exercise-induced skeletal muscle damage in postmenopausal women.
     J Appl Physiol, 107(3): 853-8. [Abstract] [Full-text]
340. A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304.
     Jpn J Clin Oncol, 39(9): 601-5. [Abstract] [Full-text]
341. A phase I study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2.
     Jpn J Clin Oncol, 39(9): 576-81. [Abstract] [Full-text]
342. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.
     Jpn J Clin Oncol, 39(9): 569-75. [Abstract] [Full-text]
343. A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer.
     Jpn J Clin Oncol, 39(9): 582-7. [Abstract] [Full-text]
344. The necessity of chemotherapy in T3N0M0 colon cancer without risk factors.
     Am J Surg, 198(3): 354-8. [Abstract] [Full-text]
345. Sclerotherapy of branchial cleft cysts using OK-432.
     Otolaryngol Head Neck Surg, 141(3): 329-34. [Abstract] [Full-text]
346. Community response to intermittent preventive treatment of malaria in infants (IPTi) delivered through the expanded programme of immunization in five African settings.
     Malar J, 8: 191. [Abstract] [Full-text]
347. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.
     J Clin Oncol, 27(25): 4055-61. [Abstract] [Full-text]
348. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer.
     J Clin Oncol, 27(25): 4116-23. [Abstract] [Full-text]
349. Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study.
     J Clin Oncol, 27(25): 4142-9. [Abstract] [Full-text]
350. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
     J Clin Oncol, 27(25): 4062-7. [Abstract] [Full-text]
351. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.
     J Clin Oncol, 27(25): 4076-81. [Abstract] [Full-text]
352. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis.
     J Clin Oncol, 27(25): 4211-6. [Abstract] [Full-text]
353. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.
     J Clin Oncol, 27(25): 4155-61. [Abstract] [Full-text]
354. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
     J Clin Oncol, 27(25): 4096-102. [Abstract] [Full-text]
355. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial.
     J Clin Oncol, 27(25): 4109-15. [Abstract] [Full-text]
356. Steady-state pharmacokinetics following application of a novel transdermal estradiol spray in healthy postmenopausal women.
     J Clin Pharmacol, 49(9): 1037-46. [Abstract] [Full-text]
357. Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients.
     Gynecol Oncol, 115(1): 97-101. [Abstract] [Full-text]
358. Effect of transdermal electromotive drug therapy on fibrogenic cytokine expression in Peyronie's disease.
     Urology, 74(3): 566-70. [Abstract] [Full-text]
359. A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172.
     Gynecol Oncol, 115(1): 81-5. [Abstract] [Full-text]
360. Small volume resuscitation with 3% hypertonic saline solution decrease inflammatory response and attenuates end organ damage after controlled hemorrhagic shock.
     Am J Surg, 198(3): 407-14. [Abstract] [Full-text]
361. Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties.
     J Control Release, 139(1): 73-80. [Abstract] [Full-text]
362. Iontophoresis-driven penetration of nanovesicles through microneedle-induced skin microchannels for enhancing transdermal delivery of insulin.
     J Control Release, 139(1): 63-72. [Abstract] [Full-text]
363. A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer.
     Lung Cancer, 66(1): 97-102. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.